Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors

Journal of Medicinal Chemistry

Volumn 39, Issue 1, 1996, Pages 217-223

  Qian, Yimin ^a   Vogt, Andreas ^a   Sebti, Saïd M ^a   Hamilton, Andrew D ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; GERANYLTRANSFERASE; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN FARNESYLTRANSFERASE; TETRAPEPTIDE;

ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

ALKYL AND ARYL TRANSFERASES; AMINO ACID SEQUENCE; BIPHENYL COMPOUNDS; CYSTEINE; DRUG DESIGN; ENZYME INHIBITORS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEIN P21(RAS); PROTEIN ISOPRENYLATION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFERASES; TUMOR CELLS, CULTURED;

EID: 0030046735     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950414g     Document Type: Article

References (34)

1. Grand, B. A.; Owen, D. The biochemistry of ras p21. Biochem. J. 1991, 279, 609-631.
2. Marshall, M. S. The effector interactions of p21ras. Trends Biochem. Sci. 1993, 18, 250-254.
3. Barbacid, M. ras genes. Annu. Rev. Biochem. 1987, 56, 779-828.
4. (a) Gibbs, J. B.; Oliff, A.; Kohl N. Farnesyltransferase Inhibitors: Ras Research Yields a Potential Cancer Therapeutic. Cell 1994, 77, 175-178.
5. (b) Der, C. J.; Cox, A. D. Isoprenoid Modification and Plasma Membrane Association: Critical Fators for Ras Oncogenicity. Cancer Cells 1991, 3, 331-340.
6. Porfiri, E.; Evans, T.; Chardin, P.; Hancock, J. F. Prenylation of Ras Proteins Is Required for Efficient hSOS1-promoted Guanine Nucleotide Exchange. J. Biol. Chem. 1994, 269, 22672-22677.
7. Hancock, J F.; Magee, J. E.; Marshall, C. J. All ras Proteins Are Polyisoprenylated but Only Some Are Palmitoylated. Cell 1989, 57, 1167-1177.
8. Casey, P. J.; Solski, P. A.; Der, C. J.; Buss, J. E. p21ras is modified by the isoprenoid farnesol. Proc. Natl Acd. Sci. U.S.A. 1989, 86, 8323-8327.
9. Gutierrez, L.; Magee, A. I.; Marshall, C. J.; Hancock, J. F. Posttranslational processing of p21ras is two-step and involves carboxylmethylation and carboxy-terminal proteolysis. EMBO J. 1989, 8, 1093-1098.
10. (a) Reiss, Y.; Seabra, M. C.; Goldstein, J. L.; Brown, M. S. Purification of ras Farnesyl Transferase. Methods 1990, 1, 241-245.
11. (b) Chen, W. J.; Moomaw, J. F.; Overton, L.; Kost, T.; Casey, P. J. High Level Expression of Mammalian Protein Farnesyltransferase in a Baculovirus System. J. Biol. Chem. 1993, 268, 9675-9680.
12. Gibbs, J. B. Ras C-Terminal Processing Enzymes-New Drug Targets. Cell 1991, 65, 1-4.
13. Casey, P. J. Biochemistry of protein prenylation. J. Lipid Res. 1992, 33, 1731-1740.
14. Casey, P. J.; Thissen, J. A.; Moomaw, J. F. Posttranslational Modification of Ha-ras p21 by farnesyl versus geranylgeranyl isoprenoids is determined by the COOH-terminal amino acid. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 8934-8938.
15. Sebra, M. C.; Goldstein, J. L.; Sudhof, T. C.; Brown, M. S. Rab Geranylgeranyl Transferase. J. Biol. Chem. 1992, 267, 14497-14503.
16. (a) Goldstein, J. L.; Brown, M. S.; Stradley, S. T.; Reiss, Y.; Gierasch, L. M. Nonfarnesylated Tetrapeptide Inhibitors of Protein Farnesyltransferase. J. Biol. Chem. 1991, 266, 15575-15578.
17. (b) Reiss, Y.; Stradley, S.; Gierasch, L.; Brown, M. S.; Goldstein, J. L. Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 732-736.
18. (a) Nigam, M.; Seong, C. M.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. Potent Inhibition of Human Tumor p21ras Farnesyltransferase by A1A2-lacking p21ras CA1A2X Peptidomimetics. J. Biol. Chem. 1993, 268, 20695-20698.
19. (b) Qian Y.; Blaskovich, M. A.; Saleem, M.; Seong, C. M.; Wathen, S. P.; Hamilton, A. D.; Sebti, S. M. Design and Structural Requirements of Potent Peptidomimetic Inhibitors of p21ras Farnesyltransferase. J. Biol. Chem. 1994, 269, 12410-12413.
20. (c) Qian, Y.; Blaskovich, M. A.; Seong, C. M.; Vogt, A.; Hamilton, A. D.; Sebti, S. M. Peptidomimetic Inhibitors of p21ras Farnesyltransferase: Hydrophobic Functionalization Leads to Disruption of p21ras Membrane Association in Whole Cells. Bioorg. Med. Chem. Lett. 1994, 4, 2579-2584.
21. (a) Kohl, N. E.; Mosser, S. D.; deSolms, S. J.; Giuliani, E. A.; Pompliano, D. L.; Graham, S. L.; Smith, R. L.; Scolnick, E. M.; Oliff, A.; Gibbs, J. B. Selective Inhibition of ras-Dependent Transformation by a Farnesyltransferase Inhibitor. Science 1993, 260, 1934-1937.
22. (b) James, G. L.; Goldstein, J. L.; Brown, M. S.; Rawson, T. E.; Somers, T. C.; McDowell, R. S.; Crowley, C. W.; Lucas, B. K.; Levinson, A. D.; Marsters, J. C. Benzodiazepine Peptidomimetics: Potent Inhibition of Ras Farnesylation in Animal Cells. Science 1993, 260, 1937-1942.
23. (c) Garcia, A. M.; Rowell, C.; Ackermann, K.; Kowalczyk, J. J.; Lewis, M. D. Peptidomimetic Inhibitors of Ras Farnesylation and Function in Whole Cells. J. Biol. Chem. 1993, 268, 18415-18418.
24. (d) Graham, S. L.; deSolms, S. J.; Giuliani, E. A.; Kohl, N. E. Mosser, S. D.; Oliff, A. I.; Pompliano, D. L.; Rands, E.; Breslin, M. J.; Deana, A. A.; Garsky, V. M.; Scholz, T. H.; Gibbs, J. B. Smith, R. L. Pseudopeptide Inhibitiors of Ras Farnesyl-Protein Transferase. J. Med. Chem. 1994, 37, 725-732.
25. (e) Bhide, R. S.; Patel, D. V.; Patel, M. M.; Robinson, S. P.; Hunihan, L. W.; Gordon, E. M. Rational Design of Potent Carboxylic Acid Based Bisubstrate Inhibitors of Ras Farnesyl Protein Transferase. Bioorg. Med. Chem. Lett. 1994, 4, 2107-2112.
26. (f) Harrington, E. M.; Kowalczyk, J. J.; Pinnow, S L.; Ackermann, K.; Garcia, A. M.; Lewis, M. D. Cysteine and Methionine Linked by Carbon Pseudopeptides Inhibit Farnesyl Transferase. Bioorg. Med. Chem. Lett. 1994, 4, 2775-2780.
27. Gardino, J.; Thompson, W. J. A General Synthesis of 5-Arylnicotinates. J. Org. Chem. 1984, 49, 5237-5243.
28. Watanabe, T.; Miyaura, N.; Suzuki, A. Synthesis of sterically Hindered Biaryls via the Palladium Catalyzed Cross-Coupling Reactions of Arylboronic Acids or Their Esters with Haloarenes. Synlett 1992, 207-210.
29. Wallow, T. I.; Novak, B. M. Highly Efficient and Accelerated Suzuki Aryl Couplings Mediated by Phosphine-Free Palladium Sources. J. Org. Chem. 1994, 59, 5034-5037.
30. Crowther, G. P.; Kaiser, E. M.; Woodruff, R. A ; Hauser, C. R. Esterification of Hindered Alcohols: t-Butyl p-Tolunate. Org. Synth. 1971, 51, 96-100.
31. Fincham, C. I.; Higginbottom, M.; Hill, D. R.; Horwell, D. C.; O'Toole, J. C.; Ratcliffe, G. S.; Rees, D. C.; Roberts, E. Amide Bond Replacements Incorporated into CCK-B Selective "Dipeptoids". J. Med. Chem. 1992, 35, 1472-1484.
32. Goel, O. P.; Krolls, U.; Stier, M.; Kesten, S. N-tert-Butoxycarbonyl-L-Leucinal. Org. Synth. 1989, 67, 69-75.
33. Pearson, D. A.; Blanchette, M.; Baker, M. L.; Guindon, C. A. Trialkylsilanes as Scavengers for Trifluoroacetic Acid Deblocking of Protecting Groups in Peptide Synthesis. Tetrahedron Lett. 1989, 30, 2739-2742.
34. Vogt, A.; Qian, Y.; Blaskovich, M. A.; Possum, R. D.; Hamilton, A. D.; Sebti, S. M. A Non-peptide Mimetic of Ras-CAAX: Selective Inhibition of Farnesyltransferase and Ras Processing. J. Biol. Chem. 1995, 270, 660-664.